IFNG and breast cancer: Taking into account that the systemic clinical use of TNF-α is impractical due to toxicity [54–56] and that IFN-γ is widely used clinically [57–59], we studied treatment of breast cancer cells with trastuzumab and pertuzumab and IFN-γ.